Glutamine blockade with JHU083 induces robust anti‐tumor immune responses in “uninflamed” and poorly immunogenic EGFR‐driven lung cancer, and JHU083 may enable EGFR‐driven lung cancer more amenable to immunoprevention and immunotherapies. This evidence concerns the gene EGFR and neoplasm.